{"url_path":"/sec/alt/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1326190/0001326190-26-000040-index.html","accession_number":"0001326190-26-000040","cik":"0001326190","ticker":"ALT","issuer_name":"Altimmune, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1326190/0001326190-26-000040-index.html","primary_entity_key":"0001326190","primary_entity_name":"Altimmune, Inc."},"word_count":45,"has_tables":true,"body_markdown":"Item 5. Other Information\n\nNone of our officers or directors adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K during the three months ended March 31, 2026.\n\n​\n\n24\n\n[Table of Contents](#TOC)"}